ConductScience.org, home

Trial · NCT01998880

Results by group130

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Progression-free Survival (PFS)Rituximab + Chlorambucil (RClb)16.595% Confidence Interval 14.3 to 17.7Months
Progression-free Survival (PFS)Chlorambucil (Clb)11.195% Confidence Interval 10.7 to 11.3Months
Percentage of Participants With Progression Free Survival EventsRituximab + Chlorambucil (RClb)90.1Percentage of participants
Percentage of Participants With Progression Free Survival EventsChlorambucil (Clb)90.7Percentage of participants
Event Free SurvivalRituximab + Chlorambucil (RClb)15.795% Confidence Interval 14.2 to 17.2Months
Event Free SurvivalChlorambucil (Clb)10.895% Confidence Interval 8.0 to 11.1Months
Overall SurvivalRituximab + Chlorambucil (RClb)74.995% Confidence Interval 60.8 to NAMonths
Overall SurvivalChlorambucil (Clb)66.795% Confidence Interval 50.9 to NAMonths
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Complete Response (CR)4.795% Confidence Interval 2.4 to 8.3Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Complete Response (CR)0.095% Confidence Interval 0.0 to 3.1Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Complete Response incomplete (CRi)2.195% Confidence Interval 0.7 to 4.9Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Complete Response incomplete (CRi)0.095% Confidence Interval 0.0 to 3.1Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Partial Response (PR)55.495% Confidence Interval 48.7 to 61.9Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Partial Response (PR)28.895% Confidence Interval 20.8 to 37.9Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Nodular Partial Response (nPR)3.495% Confidence Interval 1.5 to 6.7Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Nodular Partial Response (nPR)2.595% Confidence Interval 0.5 to 7.3Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Stable Disease13.795% Confidence Interval 9.6 to 18.8Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Stable Disease22.995% Confidence Interval 15.7 to 31.5Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Rituximab + Chlorambucil (RClb)Progressive Disease12.495% Confidence Interval 8.5 to 17.4Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)Chlorambucil (Clb)Progressive Disease28.895% Confidence Interval 20.8 to 37.9Percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01998880/results